Table 1 Clinical characteristics of patients with symptoms of itch treated with aprepitant therapy

Duval et al. (2009) [20]

3

3

Partial

VAS

9 to 2

N/A

CTCL, SS

80 mg/d

7d

7 to 2

8 to 3

Vincenzi et al. (2010) [21]

2

2

Complete

VAS

8 to 0

44F

NSCLC on erlotinib

d1: 125 mg; d2, 3: 80 mg; then 125 mg, 80 mg alternating

2m

Partial

9 to 1

74 M

Vincenzi et al. (2010) [22]

2

2

Complete

VAS

8 to 0

N/A, M

Metastatic soft tissue sarcoma

d1: 125 mg; d2, 3: 80 mg

3d

Partial

9 to 1

N/A, F

Metastatic breast carcinoma

Booken et al. (2011) [15]

5

4

Partial

VAS

Mean 9.8 to 4.3

56F

CTCL, SS

d1: 125 mg; d2, 3: 80 mg; every 2 weeks

Median 15w (range 6–24)

65F

CTCL, SS

65 M

CTCL, SS

51 M

CTCL, MF

Mir et al. (2011) [23]

1

1

Partial

Subjective

Pruritus regressed

54, N/A

NSCLC on erlotinib

80 mg/d

14d

Ladizinski et al. (2012) [24]

1

1

Partial

VAS

10 to 1

66 M

CTCL, MF

80 mg/d; 3×/week

4m

Santini et al. (2012) [14]

24

41

Complete

VAS

Median, 8 to 0

42-76 M/F

Refractory itch, metastatic solid tumor

d1: 125 mg; d3, d5: 80 mg

1w

21

Partial

Median, 8 to 1

45-70 M/F

Naïve to treatment, metastatic solid tumor

Torres et al. (2012) [25]

2

2

Partial

VAS

8 to 2

N/A

CTCL, SS

80 mg/d

15d, then every other d for 10d

9 to 3

Jimenez Gallo et al. (2013) [26]

1

1

Partial

VAS

10 to 2

41F

CTCL, MF

d1: 125 mg; d2, 3: 80 mg; every 2 weeks

N/A

Borja-Consigliere et al. (2014) [27]

1

1

Partial

VAS

10 to 3

61F

CTCL

d1: 125 mg; d2, 3: 80 mg; every 2 weeks

13m

Villafranca et al. (2014) [28]

1

1

Partial

VAS

9 to 5 after two weeks, then to 4 after one month

27F

Hodgkin’s lymphoma

80 mg/d

1m

Present cases (2017)

4

4

Complete

NRS

10 to 0

51F

CTCL, lymphomatoid papulosis/cutaneous anaplastic lymphoma

d1: 125 mg; d2, d3: 80 mg

3w; then every 3d for 12m

Partial

10 to 6; after 8 months to 2; during non-treatment weeks pruritus increases to 6

68F

CTCL, MF

every 2w for 10m

10 to 2; during non-treatment weeks pruritus increased back to 10

64 M

every 2w for 6m

10 to 4

59 M

1m

Ally et al. (2013) [29]

1

1

Partial

Subjective

Vast improvement

61F

Brachioradial pruritus

80 mg/d

2w

Complete

8 to 0

66F

Multifactorial (hyperuricemia, iron deficiency)

8 to 0

50F

Unknown

Stander et al. (2010) [13]

20

16

Partial

VAS

8 to 1

42 M

Multifactorial (thyroid dysfunction, neurogenic)

80 mg/d

6.6d (range 3–13)

10 to 3

59F

Multifactorial (metabolic syndrome)

10 to 4

73F

Multifactorial (renal, diabetes)

10 to 5

55F

Multifactorial (cholestatic, dry skin, psychosomatic factors)

10 to 5

52F

Unknown

8 to 4

78 M

Renal

6 to 3

72 M

Unknown

8 to 5

36 M

Unknown

7 to 4

72 M

Renal

5 to 3

66F

Multifactorial (renal, dry skin)

7 to 5

69 M

Renal

10 to 8

82F

Multifactorial (renal, hyperuricemia)

7 to 6

81F

Unknown

10 to 9

85F

Unknown